Editorial Note on Developing an HIV Vaccine: Vaccinology Research

Abstract

It is widely acknowledged that eradicating HIV from the human population will necessitate the development of an effective vaccine. Candidate vaccines that have been tested to date, on the other hand, have either failed or demonstrated very low and debatable efficacy. New vaccine trials based on producing both antibodies and T cell immunity have begun, and the findings of these trials will be known in the coming years. Simultaneously, a large body of evidence suggests that broadly neutralising antibodies (bnAbs) are created in natural HIV infection and that such antibody, delivered via passive transfer, can protect against HIV in animal models as well as alter HIV infection in humans.